Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $962,190.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00. Following the completion of the transaction, the insider owned 126,019 shares of the company’s stock, valued at approximately $40,418,073.87. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.

Natera Stock Up 0.2%

Shares of Natera stock opened at $328.18 on Friday. The firm has a market cap of $47.30 billion, a PE ratio of -241.31 and a beta of 1.54. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $343.18. The business has a 50-day moving average price of $292.62 and a 200 day moving average price of $237.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned ($0.74) earnings per share. On average, sell-side analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of NTRA. California State Teachers Retirement System lifted its position in Natera by 28,373.5% in the second quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company’s stock valued at $15,289,364,000 after buying an additional 56,126,974 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Natera in the 2nd quarter valued at approximately $2,962,770,000. Wellington Management Group LLP raised its stake in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Finally, State Street Corp lifted its holdings in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NTRA shares. JPMorgan Chase & Co. boosted their target price on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $375.00 price objective on Natera in a report on Friday, August 7th. Sanford C. Bernstein assumed coverage on Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. Barclays reissued an “overweight” rating and set a $340.00 target price on shares of Natera in a report on Friday, August 7th. Finally, Leerink Partners set a $330.00 target price on Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.